TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28256358
Drug: MVA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA vaccine subcutaneously by S&N on Days 1 and 22
Study: 28256358
Drug: MVA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA vaccine subcutaneously by JI on Days 1 and 29
Study: 28257602
Drug: Temporary steroids
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary steroids while background immunosuppressants were withdrawn
Study: 28257602
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy resumed when symptoms recurred
Study: 28261651
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg daily + Cisplatin 75 mg/m²
Study: 28261656
Drug: BIW-8962 (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIW-8962 (monoclonal antibody to GM2 ganglioside)
Study: 28262342
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + dipyrone
Study: 28262724
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist monotherapy
Study: 28264796
Drug: Jawbone Up24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jawbone Up24 monitor, tablet with Jawbone Up app, brief weekly telephone counseling for 12 weeks
Study: 28264833
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant treatment (no AC)
Study: 28265478
Drug: Twice-daily pramipexole
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily pramipexole extended release (PER) regimen
Study: 28265478
Drug: Once-daily pramipexole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily pramipexole extended release (PER) regimen
Study: 28265861
Drug: Human urinary
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human urinary kallidinogenase (HUK) administered by intravenous drip once daily for 21 consecutive days
Study: 28266092
Drug: HPV-16/18 AS04-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 AS04-adjuvanted vaccine (3 doses at 0, 1, and 6 months)
Study: 28268087
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT; acetylsalicylic acid [ASA] + ADP receptor inhibitor [ADPri], mainly clopidogrel)
Study: 28268087
Drug: Antithrombotic drug
Normalized name: Heparin group antithrombotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic drug (most commonly ASA)
Study: 28270022
Drug: AR-42, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-42, an oral pan-HDAC inhibitor, 40 mg dosed three times weekly for three weeks of a 28-day cycle
Study: 28270121
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (not explicitly mentioned in the abstract)
Study: 28270162
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of paclitaxel (50 mg/m) and 5-fluorouracil (5-FU) with concurrent radiation therapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx) followed by 2 cycles of consolidation chemotherapy
Study: 28270212
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa 150 μg every other week combined with hCG twice-weekly for 52 weeks
Study: 28270435
Drug: Multikinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multikinase inhibitors initiated at study entry (cohort 1)
Study: 28270435
Drug: No multikinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No multikinase inhibitors initiated at study entry (cohort 2)
Study: 28271639
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) using CyberKnife technology, 36.25 Gy in five fractions
Study: 28271639
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) using CyberKnife technology
Study: 28273780
Drug: Disease-modifying therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying therapies (DMTs) - 33% oral, 66% injectable
Study: 28273780
Drug: Oral DMTs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DMTs
Study: 28274211
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose ablative radiation treatment (20 Gy to the tumor and 15 Gy to the tumor bed)
Study: 28274235
Drug: Pre-epiglottic baton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-epiglottic baton plate (PEBP) treatment
Study: 28274904
Drug: Combination HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HIV prevention package including HIV testing and counseling, voluntary medical circumcision, condoms for males, PrEP, conditional cash transfer, contraceptives for females, and referrals for HIV care.
Study: 28274904
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health teams delivering the combination HIV prevention package.
Study: 28274904
Drug: Age- and
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age- and gender-specific combination HIV prevention interventions.
Study: 28275119
Drug: Pilaralisib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilaralisib (200 mg QD) in combination with paclitaxel and carboplatin
Study: 28275958
Drug: Other DPP-4
Normalized name: PPG-4 myristyl ether
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other DPP-4 inhibitors (linagliptin, saxagliptin, sitagliptin, vildagliptin) at their recommended daily doses
Study: 28277349
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy during pregnancy (various adherence levels and durations)
Study: 28277349
Drug: No antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiretroviral therapy during pregnancy
Study: 28277349
Drug: Viral load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral load greater than 1,000 copies/mL
Study: 28277702
Drug: 8-session group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-session group-based weekly comprehensive trauma management and smoking cessation treatment focusing on skills to alleviate PTSD symptoms.
Study: 28280103
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel treatment; genetic polymorphisms assessed by MassARRAY method.
Study: 28280887
Drug: Brivaracetam 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 2.0 mg/kg bid (maximum 100 mg bid for body weight >50 kg)
Study: 28280887
Drug: Brivaracetam co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam co-administered with phenobarbital
Study: 28280887
Drug: Brivaracetam co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam co-administered with carbamazepine
Study: 28280887
Drug: Brivaracetam co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam co-administered with valproate
Study: 28280901
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (screening plus training and support in intensive multifactorial treatment)
Study: 28280971
Drug: LY3022859 infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022859 infused IV at 1.25 mg/kg over 1 h every 2 weeks (cohort 1A)
Study: 28280971
Drug: LY3022859 infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022859 infused IV at flat doses of 12.5 mg (cohort 1B)
Study: 28280971
Drug: LY3022859 infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022859 infused IV at flat doses of 25 mg (cohort 2)
Study: 28280971
Drug: LY3022859 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3022859 at 25 mg dose level after fifth infusion
Study: 28281183
Drug: Buparlisib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (100 mg/daily) plus high dose carboplatin (AUC 6) and paclitaxel (200 mg/m2) in Cohort A
Study: 28281183
Drug: Buparlisib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (100 mg/daily) plus standard dose carboplatin (AUC 5) and paclitaxel (175 mg/m2) in Cohort B
Study: 28281731
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (ASA + clopidogrel)
Study: 28282271
Drug: Lambda/RBV/DCV for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lambda/RBV/DCV for 12 weeks, followed by Lambda/RBV for an additional 12 weeks in cohort A; response-guided therapy in cohort B.
Study: 28282585
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (2.7 g/day of EPA+DHA)
Study: 28282585
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1.8 g/day of EPA+DHA)
Study: 28283497
Drug: Limit of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limit of detection (LOD, hs-cTnI<2 ng/L)
Study: 28283497
Drug: Single cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cutoff (hs-cTnI<5 ng/L)
Study: 28283497
Drug: 1-hour algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour algorithm (hs-cTnI<5 ng/L and 1-hour change<2 ng/L)
Study: 28283699
Drug: Low-dose end-expiratory
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose end-expiratory CT scans at PEEP 5 and 15 cmH2O
Study: 28284916
Drug: Mesenchymal stromal
Normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stromal cell (MSC) infusion (1.5-3×10^6 cells)
Study: 28284916
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard immunosuppression without MSC infusion)
Study: 28285070
Drug: Treatment-level FRAX
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-level FRAX score calculation with bone mineral density
Study: 28285240
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy associated with SKY (Treatment)
Study: 28285311
Drug: Wearable sensor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable sensor monitoring of spontaneous daily physical activity (PAMSys™, BioSensics LLC)
Study: 28286803
Drug: D2C7-(scdsFv)-PE38KDEL (D2C7-IT)
Normalized name: D2C7 immunotoxin
DrugBank: D2C7 immunotoxin (DB17540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2C7-(scdsFv)-PE38KDEL (D2C7-IT) immunotoxin therapy
Study: 28288678
Drug: Care Coordination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care Coordination Intervention (CCI) consisting of a tablet-based mobile platform, interagency communication protocol, and training protocol.
Study: 28288682
Drug: ADA discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA discontinuation (n=74)
Study: 28288682
Drug: Initial intensive
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial intensive therapy (ADA + MTX)
Study: 28288963
Drug: High on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High on-treatment platelet reactivity (HPR) defined as P2Y12 reaction units >208
Study: 28289025
Drug: Low-dose primaquine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose primaquine
Study: 28289215
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement kit consisting of monoamine precursor amino acids and dietary antioxidants (including tryptophan and tyrosine)
Study: 28289402
Drug: Pasireotide SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide SC injection
Study: 28290120
Drug: Intravenous clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clindamycin dosing of 9 mg/kg/dose for children ≤5 months, 12 mg/kg/dose for children >5 months-6 years, and 10 mg/kg/dose for children 6-18 years, administered every 8 hours.
Study: 28290120
Drug: Optimal dosing
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal dosing proposed by the pediatric PBPK model.
Study: 28291640
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (initial dose 450 μg subcutaneously once per week, reduced to 90 mg per week)
Study: 28291870
Drug: Evolocumab, 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab, 420 mg plus standard of care (SOC)
Study: 28291870
Drug: Evolocumab, 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab, 420 mg plus SOC
Study: 28291870
Drug: Evolocumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab treatment
Study: 28292941
Drug: BAY 1129980
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 1129980 (C4.4A-ADC), an antibody-drug conjugate targeting C4.4A
Study: 28293270
Drug: Moringa (1.85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa (1.85 g leaf powder/day)
Study: 28293280
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg of ramosetron
Study: 28296283
Drug: Transendocardial CD34
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial CD34 treatment, details on dosage and duration not provided
Study: 28298401
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after radiation therapy (SMART)
Study: 28299283
Drug: Lenvatinib 24
Normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 24 mg daily until disease progression or unacceptable toxicity
Study: 28302090
Drug: Chemotherapy-alone regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-alone regimens
Study: 28303154
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs); specific dosage and duration not mentioned.
Study: 28303154
Drug: Not specified;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not specified; ongoing studies include MSCs therapy in emphysema and several studies of ADSCs in COPD.
Study: 28314691
Drug: Dexamethasone mouthwash
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone mouthwash (10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL oral solution, swish for 2 min and spit, four times daily for 8 weeks)
Study: 28314691
Drug: Historical controls
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical controls from the BOLERO-2 trial (everolimus and exemestane treatment without dexamethasone mouthwash)
Study: 28315940
Drug: Multi-faceted intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-faceted intervention including low tidal volume (≤7 ml/kg), moderate PEEP (6-8 cm H2O), and early extubation.
Study: 28318636
Drug: Peripheral Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral Laser Treatment
Study: 28320242
Drug: Early, goal-directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early, goal-directed therapy (EGDT)
Study: 28323923
Drug: Ligand-receptor variant
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligand-receptor variant combination resulting in weak FSH action
Study: 28323960
Drug: Serum phosphate
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum phosphate and renal phosphate excretion
Study: 28323970
Drug: Serum and
Normalized name: Nivea Deep Nourishing Serum and Almond Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum and FF hormone and lipid levels in OW women
Study: 28324018
Drug: Highest TSH
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Highest TSH tertile (2.14 to 86.7 mIU/L)
Study: 28324018
Drug: Lowest TSH
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lowest TSH tertile (<1.28 mIU/L)
Study: 28324042
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (anakinra/Kineret®, total dose 3 × 100 mg)
Study: 28324749
Drug: SAR405838 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR405838 400 mg QD
Study: 28324749
Drug: SAR405838 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR405838 300 mg QD
Study: 28324749
Drug: SAR405838 weekly
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SAR405838 weekly schedule
Study: 28324749
Drug: SAR405838 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR405838 1800 mg twice weekly
Study: 28325399
Drug: Hedgehog pathway
Normalized name: Hedgehog pathway inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hedgehog pathway inhibitor therapy
Study: 28325857
Drug: Laser treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment, cryotherapy, vascular endothelial growth factor (VEGF) inhibitor, vitrectomy/scleral buckling, or a combination thereof.
Study: 28326189
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg + csDMARDs
Study: 28326189
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg + csDMARDs
Study: 28327200
Drug: LY2787106 (0.3-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2787106 (0.3-10 mg/kg every 3 weeks)
Study: 28327200
Drug: LY2787106 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2787106 (10 mg/kg weekly)
Study: 28327905
Drug: Idelalisib 150
Normalized name: idelalisib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib 150 mg two times daily (increased to 300 mg two times daily at disease progression)
Study: 28329286
Drug: MGN1703 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGN1703 (60 mg subcutaneously twice weekly for 4 weeks)
Study: 28329385
Drug: Combined left
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined left atrial volume index (LAVI) >40 ml/m2 and tricuspid regurgitation (TR) >3.1 m/s
Study: 28330462
Drug: Everolimus, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus, administered orally at a daily dose of 10 mg continuously (28-day cycles).
Study: 28330670
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LFP and bright spots
Study: 28331539
Drug: Ramosetron 5
Normalized name: alosetron 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 5 μg
Study: 28331611
Drug: One ultrasound-guided
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One ultrasound-guided high-intensity focused ultrasound (HIFU) treatment
Study: 28331611
Drug: Two ultrasound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ultrasound-guided high-intensity focused ultrasound (HIFU) treatments
Study: 28333704
Drug: High PLT:RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High PLT:RBC ratio (≥0.2 PLT doses:1 RBC unit)
Study: 28333976
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin I (hs-TnI) baseline cutoff of 150 ng/L
Study: 28333976
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin I (hs-TnI) change of 20 ng/L after 1 hour
Study: 28335798
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg subcutaneous daily (with escalation to 200 mg and 300 mg)
Study: 28335798
Drug: Anakinra 200
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 200 mg
Study: 28335798
Drug: Anakinra 300
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 300 mg
Study: 28335798
Drug: Anakinra (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (all doses)
Study: 29304833
Drug: Selinexor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (60 mg)
Study: 28336743
Drug: Lower socioeconomic
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower socioeconomic position (SEP) indicators such as fewer assets and having a daily wage labourer as the highest occupation.
Study: 28337324
Drug: GBT440 (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBT440 (dosage and duration not specified)
Study: 28337781
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management (antithrombotic therapy)
Study: 28339149
Drug: Tenapanor hydrochloride
Normalized name: Tenapanor hydrochloride
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenapanor hydrochloride 15 mg twice daily before food
Study: 28339149
Drug: Tenapanor hydrochloride
Normalized name: Tenapanor hydrochloride
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenapanor hydrochloride 15 mg twice daily after food
Study: 28339149
Drug: Tenapanor hydrochloride
Normalized name: Tenapanor hydrochloride
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenapanor hydrochloride 15 mg twice daily while fasting
Study: 28341495
Drug: TMX-101 (200mg/50ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMX-101 (200mg/50ml, 0.4%) administered intravesically for 6 weeks
Study: 28341957
Drug: pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated liposomal doxorubicin 30 mg/m² plus lapatinib